We need you! Join our contributor community and become a WikEM editor through our open and transparent promotion process.
Parvovirus B19
From WikEM
Contents
Background
- In children: causes Erythema infectiosum (Fifth disease)
- In transplant patients on immunosuppressive drugs: causes RBC aplasia.
- Short-lived, may not be discovered
- Parvovirus only replicated in erythroid progenitor cells
Clinical Features
- Erythema infectiosum (fifth disease)
- Most contagious during the phase of active viral replication and viral shedding, which occurs approximately 5 to 10 days after exposure and usually lasts approximately 5 days
- Complications
- Arthropathy
- Aplastic anemia
Differential Diagnosis
Evaluation
- Diagnosis is clinical usually through clinical presentation
- IgM testing is recommended for immunocompromised patients.
Management
- Parvovirus is usually self-limiting and requires no further treatment.
- Management should be targeted at reducing symptoms, such as using anti-inflammatory medications for arthropathy or performing transfusions for aplastic anemia.
Disposition
See Also
External Links
References
- Fish RM, Massad MG. The Transplant Patient. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. New York, NY: McGraw-Hill; 2011.
- Place R, Lagoc AT, Mayer TA, Lawlor CJ. Oncology and Hematology Emergencies in Children. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. New York, NY: McGraw-Hill; 2011
